We congratulate Dr. Glenn Dranoff, a 2010 ACGT Fellow, in his new role as Global Head of Exploratory Immuno-oncology at Novartis. The company entered into a multiyear alliance with Aduro Biotech to promote the discovery and development of next generation immunotherapies targeting the STING (Stimulator of Interferon Genes) pathway, and launched a new immuno-oncology research group led by renowned cancer vaccine expert Dranoff.
While professor of medicine at Dana-Farber Cancer Institute and Harvard Medical School, Dr. Dranoff developed a basic and translational research program to explain the cellular and molecular mechanisms underlying the generation of anti-tumor immunity. His laboratory has defined the biologic activity of several cancer immunotherapies in patients with solid or hematologic malignancies, which helped provide the foundation for the recent FDA approvals of the first therapeutic cancer vaccine and the first monoclonal antibody that blocks negative immune regulation.
